Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases

4

Regina H. Reynolds^{1,2,#}, Aaron Z. Wagen^{1,3,4,#}, Frida Lona-Durazo⁵, Sonja W. Scholz^{6,7}, Maryam
 Shoai^{8,10}, John Hardy^{28,10}, Sarah A. Gagliano Taliun^{5,9}, Mina Ryten^{1,2,11}

7 [#] These authors contributed equally to this work.

8 Author affiliations

- 9 1. Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University 10 College London, London, UK 11 2. Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, 12 MD 20815, United States 13 3. Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, 14 London, UK 15 4. Neurodegeneration Biology Laboratory, The Francis Crick Institute, London, UK 16 5. Montréal Heart Institute, Montréal, Québec, Canada 17 6. Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and 18 Stroke, Bethesda, MD, USA 19 7. Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD, USA 8. Department of Neurodegenerative Diseases, Queen Square Institute of Neurology, 20 21 University College London, London, UK 9. Department of Medicine & Department of Neurosciences, Université de Montréal, Montréal, 22 23 Québec, Canada 24 10. UK Dementia Research Institute, University College London, London, UK 25 11. NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London, London, UK 26 27 28 **Correspondence to:** Regina H. Reynolds (regina.reynolds.16@ucl.ac.uk) & Mina Ryten
- 29 (mina.ryten@ucl.ac.uk)

30 Abstract

31	Genetic correlation (r_g) between traits can offer valuable insight into underlying shared biological
32	mechanisms. Neurodegenerative diseases overlap neuropathologically and often manifest comorbid
33	neuropsychiatric symptoms. However, global r_g analyses show minimal r_g among neurodegenerative
34	and neuropsychiatric diseases. Importantly, local r_g s can exist in the absence of global relationships.
35	To investigate this possibility, we applied LAVA, a tool for local r_g analysis, to genome-wide
36	association studies of 3 neurodegenerative diseases (Alzheimer's disease, Lewy body dementia and
37	Parkinson's disease) and 3 neuropsychiatric disorders (bipolar disorder, major depressive disorder
38	and schizophrenia). We identified several local r_g s missed in global analyses, including between (i) all
39	3 neurodegenerative diseases and schizophrenia and (ii) Alzheimer's and Parkinson's disease. For
40	those local r_g s identified in genomic regions containing disease-implicated genes, such as SNCA, CLU
41	and APOE, incorporation of expression quantitative trait loci suggested that genetic overlaps
42	between diseases may be driven by more than one gene. Collectively, we demonstrate that complex
43	genetic relationships exist among neurodegenerative and neuropsychiatric diseases, highlighting
44	putative pleiotropic genomic regions and genes. These findings imply sharing of pathogenic
45	processes and the potential existence of common therapeutic targets.
46	Abbreviations: AD = Alzheimer's disease; BIP = bipolar disorder; bp = base pair; CI = confidence
47	interval; DLB = dementia with Lewy bodies; eQTL = expression quantitative loci; FDR = false discovery
48	rate; GWAS = genome-wide association study; kb = kilobase; LAVA = local analysis of [co]variant
49	annotation; LBD = Lewy body dementia; LD = linkage disequilibrium; LDSC = linkage disequilibrium
50	score regression; MDD = major depressive disorder; PD = Parkinson's disease; SCZ = schizophrenia;
51	SNP = single nucleotide polymorphism; UKBB = UK Biobank; $ ho$ = rho; r_g = genetic correlation

52 Introduction

53	Neurodegenerative diseases are a group of syndromically-defined disorders that are characterised
54	by the progressive loss of the structure and function of the central nervous system. They are
55	typically grouped by their predominant neuropathological protein deposit (e.g. synucleinopathies by
56	lpha-synuclein deposition), but more often than not, they present with co-pathologies, suggesting that
57	they might share common pathogenic pathways ^{1,2} . This notion is supported by genome-wide
58	association studies (GWASs), which have (i) identified shared risk loci across neurodegenerative
59	diseases, such as APOE and BIN1 in Alzheimer's disease (AD) and Lewy body dementia (LBD), or GBA,
60	SNCA, TMEM175 in Parkinson's disease (PD) and LBD and (ii) demonstrated that genetic risk scores
61	derived from one neurodegenerative disease can predict risk of another, as with AD and PD scores
62	predicting risk of LBD ^{3–5} . The importance of identifying common pathogenic processes cannot be
63	overstated, given the implications for our mechanistic understanding of these diseases as well as
64	identification of common therapeutic targets benefitting a wider range of patients.
65	From a clinical perspective, neurodegenerative diseases are often also defined in terms of their
65 66	From a clinical perspective, neurodegenerative diseases are often also defined in terms of their predominant symptom (e.g. AD by memory impairment or PD by parkinsonism), but in reality,
65 66 67	From a clinical perspective, neurodegenerative diseases are often also defined in terms of their predominant symptom (e.g. AD by memory impairment or PD by parkinsonism), but in reality, present as highly heterogenous diseases, with symptoms spanning multiple domains including
65 66 67 68	From a clinical perspective, neurodegenerative diseases are often also defined in terms of their predominant symptom (e.g. AD by memory impairment or PD by parkinsonism), but in reality, present as highly heterogenous diseases, with symptoms spanning multiple domains including neuropsychiatric symptoms ^{6,7} . Indeed, a higher prevalence of depression has been observed in
65 66 67 68 69	From a clinical perspective, neurodegenerative diseases are often also defined in terms of their predominant symptom (e.g. AD by memory impairment or PD by parkinsonism), but in reality, present as highly heterogenous diseases, with symptoms spanning multiple domains including neuropsychiatric symptoms ^{6,7} . Indeed, a higher prevalence of depression has been observed in individuals with dementia compared to those without dementia. ⁸ Furthermore, depression and
65 66 67 68 69 70	From a clinical perspective, neurodegenerative diseases are often also defined in terms of their predominant symptom (e.g. AD by memory impairment or PD by parkinsonism), but in reality, present as highly heterogenous diseases, with symptoms spanning multiple domains including neuropsychiatric symptoms ^{6,7} . Indeed, a higher prevalence of depression has been observed in individuals with dementia compared to those without dementia. ⁸ Furthermore, depression and anxiety are more common in individuals with PD compared to the general population, with clinically
65 66 67 68 69 70 71	From a clinical perspective, neurodegenerative diseases are often also defined in terms of their predominant symptom (e.g. AD by memory impairment or PD by parkinsonism), but in reality, present as highly heterogenous diseases, with symptoms spanning multiple domains including neuropsychiatric symptoms ^{6,7} . Indeed, a higher prevalence of depression has been observed in individuals with dementia compared to those without dementia. ⁸ Furthermore, depression and anxiety are more common in individuals with PD compared to the general population, with clinically significant symptoms in 30-35% of patients ^{9,10} . A similar (albeit reversed) phenomenon has been
65 66 67 68 69 70 71 72	From a clinical perspective, neurodegenerative diseases are often also defined in terms of their predominant symptom (e.g. AD by memory impairment or PD by parkinsonism), but in reality, present as highly heterogenous diseases, with symptoms spanning multiple domains including neuropsychiatric symptoms ^{6,7} . Indeed, a higher prevalence of depression has been observed in individuals with dementia compared to those without dementia. ⁸ Furthermore, depression and anxiety are more common in individuals with PD compared to the general population, with clinically significant symptoms in 30-35% of patients ^{9,10} . A similar (albeit reversed) phenomenon has been
 65 66 67 68 69 70 71 72 73 	From a clinical perspective, neurodegenerative diseases are often also defined in terms of their predominant symptom (e.g. AD by memory impairment or PD by parkinsonism), but in reality, present as highly heterogenous diseases, with symptoms spanning multiple domains including neuropsychiatric symptoms ^{6,7} . Indeed, a higher prevalence of depression has been observed in individuals with dementia compared to those without dementia. ⁸ Furthermore, depression and anxiety are more common in individuals with PD compared to the general population, with clinically significant symptoms in 30-35% of patients ^{9,10} . A similar (albeit reversed) phenomenon has been observed in some neuropsychiatric disorders, with a higher risk of dementia diagnoses observed in individuals with schizophrenia (SCZ) versus individuals without a history of serious mental illness ^{11,12}
65 66 67 68 69 70 71 72 73 74	From a clinical perspective, neurodegenerative diseases are often also defined in terms of their predominant symptom (e.g. AD by memory impairment or PD by parkinsonism), but in reality, present as highly heterogenous diseases, with symptoms spanning multiple domains including neuropsychiatric symptoms ^{6,7} . Indeed, a higher prevalence of depression has been observed in individuals with dementia compared to those without dementia. ⁸ Furthermore, depression and anxiety are more common in individuals with PD compared to the general population, with clinically significant symptoms in 30-35% of patients ^{9,10} . A similar (albeit reversed) phenomenon has been observed in some neuropsychiatric disorders, with a higher risk of dementia diagnoses observed in individuals with schizophrenia (SCZ) versus individuals without a history of serious mental illness ^{11,12} and a higher risk of PD in individuals diagnosed with depressive disorder in mid or late life ^{10,13,14} .
 65 66 67 68 69 70 71 72 73 74 75 	From a clinical perspective, neurodegenerative diseases are often also defined in terms of their predominant symptom (e.g. AD by memory impairment or PD by parkinsonism), but in reality, present as highly heterogenous diseases, with symptoms spanning multiple domains including neuropsychiatric symptoms ^{6,7} . Indeed, a higher prevalence of depression has been observed in individuals with dementia compared to those without dementia. ⁸ Furthermore, depression and anxiety are more common in individuals with PD compared to the general population, with clinically significant symptoms in 30-35% of patients ^{9,10} . A similar (albeit reversed) phenomenon has been observed in some neuropsychiatric disorders, with a higher risk of dementia diagnoses observed in individuals with schizophrenia (SCZ) versus individuals without a history of serious mental illness ^{11,12} and a higher risk of PD in individuals diagnosed with depressive disorder in mid or late life ^{10,13,14} . Together, these observations suggest the possibility of intersecting pathways between

77	Importantly, clinical and neuropathological overlaps are not reflected in global genetic correlations
78	(r_g), with a recent study of global r_g between neurological phenotypes demonstrating limited
79	overlap between individual neurodegenerative diseases as well as between neurodegenerative
80	diseases and neuropsychiatric disorders ^{15,16} . One explanation for the lack of global genetic
81	correlation is that global studies only consider the average r_g across the entire genome. A genome-
82	wide average of r_g may fail to detect strong local r_g s confined to specific genomic regions or local r_g s
83	that have opposing directions across the genome ^{15,17} . This limitation can be addressed with recently-
84	developed bioinformatics tools such as <u>l</u> ocal <u>a</u> nalysis of [co] <u>v</u> ariant <u>a</u> nnotation (LAVA), which is able
85	to evaluate local heritability over multiple traits of interest (using summary statistics) and detect
86	local regions of shared genetic association ¹⁸ . Here, we apply LAVA to GWASs derived from 3
87	neurogenerative diseases (AD, LBD and PD) ^{3,5,19,20} and 3 neuropsychiatric disorders (bipolar disorder,
88	BIP; major depressive disorder, MDD; and SCZ) $^{21-23}$. In addition, we use data from blood- and brain-
89	derived gene expression traits, in the form of expression quantitative loci (eQTLs), to facilitate
90	functional interpretation of local r_g s between disease traits.

91 **Results**

92 Local analyses reveal genetic correlations among neurodegenerative and

93 neuropsychiatric diseases

94 We applied LAVA to 3 neurodegenerative diseases (AD, LBD and PD) and 3 neuropsychiatric disorders (BIP, MDD and SCZ) (**Table 1**), all of which represent globally prevalent diseases²⁴. Among 95 96 neurodegenerative diseases, AD and PD are the most common, with a global prevalence of 8.98% 97 and 1.12% in individuals > 70 years of age^{6,24,25} and consequently, have large GWAS cohorts (AD, N cases = 71,880; PD, N cases = 33,674)^{3,19}. LBD is the second most common dementia subtype after 98 AD, affecting between 4.2-30% of dementia patients²⁶. As such, the LBD GWAS cohort is small (N 99 100 cases = 2,591), but unlike AD and PD neurodegenerative GWASs, 69% of the cohort is pathologically 101 defined⁵. Among neuropsychiatric disorders, MDD is the second most prevalent, with an estimated 102 185 million people affected globally (equivalent to 2.49% of the general population), while BIP and SCZ have a prevalence of 0.53% and 0.32%, respectively²⁴. Accordingly, all 3 disorders have large, 103 well-powered GWASs (BIP, N cases = 41,917; MDD, N cases = 170,756; SCZ, N cases = 40,675)²¹⁻²³. 104 105 We tested pairwise local genetic correlations $(r_a s)$ across a targeted subset of 300 local autosomal 106 genomic regions that contain genome-wide significant GWAS loci from at least one trait 107 (Supplementary Figure 1, Supplementary Table 1). These genomic regions, henceforth referred to 108 as linkage disequilibrium (LD) blocks, were filtered from the original 2,495 LD blocks generated by Werme et al.¹⁸ using a genome-wide partitioning algorithm that aims to reduce LD between LD 109 110 blocks. 111 First, we performed a univariate test for every disease trait at each of the 300 LD blocks to ensure

sufficient local genetic signal was present to proceed with bivariate local r_g analyses. Pairs of traits exhibiting a univariate local genetic signal of p < 0.05/300 were then carried forward to bivariate tests, resulting in 1,603 bivariate tests across 275 distinct LD blocks. Using a Bonferroni-corrected pvalue threshold of p < 0.05/1,603, we detected 77 significant bivariate local r_g s across 59 distinct LD

116	blocks, with 25 local r_g s between trait pairs where no significant global r_g was observed (Figure 1a,
117	Figure 1b, Supplementary Table 2, Supplementary Table 3). These 25 correlations included: (i) local
118	r_g s between all 3 neurodegenerative diseases and SCZ; (ii) a local r_g between PD and BIP; and (ii) 20
119	local r_g s between AD and PD.
120	For 30 of the 77 local r_g s, the genetic signal of both disease traits may overlap entirely, suggested by
121	the upper limit of the 95% confidence interval (CI) for explained variance (i.e. r^2 , the proportion of
122	variance in genetic signal of one disease trait in a pair explained by the other) including 1. Notably,
123	the trait pairs where the upper limit of the 95% CI did not include 1 all involved at least one
124	neurodegenerative disease, with the one exception being a local r_g between PD and SCZ, suggesting
125	that the genetic overlap between neurodegenerative diseases is smaller than between
126	neuropsychiatric disorders in the tested LD blocks (Figure 1c).
127	
128	Local analyses associate disease-implicated genomic regions with previously
128 129	Local analyses associate disease-implicated genomic regions with previously unrelated traits
128 129 130	Local analyses associate disease-implicated genomic regions with previously unrelated traits Across the 77 local r_g s, 22 involved trait pairs where both traits had genome-wide significant single
128 129 130 131	Local analyses associate disease-implicated genomic regions with previously unrelated traits Across the 77 local r_g s, 22 involved trait pairs where both traits had genome-wide significant single nucleotide polymorphisms (SNPs) overlapping the LD block tested, 35 involved trait pairs where one
128 129 130 131 132	Local analyses associate disease-implicated genomic regions with previously unrelated traits Across the 77 local r_g s, 22 involved trait pairs where both traits had genome-wide significant single nucleotide polymorphisms (SNPs) overlapping the LD block tested, 35 involved trait pairs where one trait in the pair had genome-wide significant SNPs overlapping the LD block tested and 20 involved
128 129 130 131 132 133	Local analyses associate disease-implicated genomic regions with previously unrelated traits Across the 77 local r_g s, 22 involved trait pairs where both traits had genome-wide significant single nucleotide polymorphisms (SNPs) overlapping the LD block tested, 35 involved trait pairs where one trait in the pair had genome-wide significant SNPs overlapping the LD block tested and 20 involved trait pairs where neither trait had genome-wide significant SNPs overlapping the LD block tested
128 129 130 131 132 133 134	Local analyses associate disease-implicated genomic regions with previously unrelated traits Across the 77 local r_g s, 22 involved trait pairs where both traits had genome-wide significant single nucleotide polymorphisms (SNPs) overlapping the LD block tested, 35 involved trait pairs where one trait in the pair had genome-wide significant SNPs overlapping the LD block tested and 20 involved trait pairs where neither trait had genome-wide significant SNPs overlapping the LD block tested and 20 involved
128 129 130 131 132 133 134 135	Local analyses associate disease-implicated genomic regions with previously unrelated traits Across the 77 local r_g s, 22 involved trait pairs where both traits had genome-wide significant single nucleotide polymorphisms (SNPs) overlapping the LD block tested, 35 involved trait pairs where one trait in the pair had genome-wide significant SNPs overlapping the LD block tested and 20 involved trait pairs where neither trait had genome-wide significant SNPs overlapping the LD block tested (Figure 2a). Thus, despite the targeted nature of our approach (which biased analyses towards LD blocks that contain genome-wide significant GWAS SNPs), 71% of the detected local r_g s linked
128 129 130 131 132 133 134 135 136	Local analyses associate disease-implicated genomic regions with previously unrelated traits Across the 77 local r_g s, 22 involved trait pairs where both traits had genome-wide significant single nucleotide polymorphisms (SNPs) overlapping the LD block tested, 35 involved trait pairs where one trait in the pair had genome-wide significant SNPs overlapping the LD block tested and 20 involved trait pairs where neither trait had genome-wide significant SNPs overlapping the LD block tested (Figure 2a). Thus, despite the targeted nature of our approach (which biased analyses towards LD blocks that contain genome-wide significant GWAS SNPs), 71% of the detected local r_g s linked genomic regions implicated by one of the six disease traits with seemingly unrelated disease traits.
128 129 130 131 132 133 134 135 136 137	Local analyses associate disease-implicated genomic regions with previously unrelated traits Across the 77 local r_g s, 22 involved trait pairs where both traits had genome-wide significant single nucleotide polymorphisms (SNPs) overlapping the LD block tested, 35 involved trait pairs where one trait in the pair had genome-wide significant SNPs overlapping the LD block tested and 20 involved trait pairs where neither trait had genome-wide significant SNPs overlapping the LD block tested (Figure 2a). Thus, despite the targeted nature of our approach (which biased analyses towards LD blocks that contain genome-wide significant GWAS SNPs), 71% of the detected local r_g s linked genomic regions implicated by one of the six disease traits with seemingly unrelated disease traits. For example, LD block 1719 and 2281 both contained genome-wide significant GWAS SNPs from
128 129 130 131 132 133 134 135 136 137 138	Local analyses associate disease-implicated genomic regions with previously unrelated traits Across the 77 local r_g s, 22 involved trait pairs where both traits had genome-wide significant single nucleotide polymorphisms (SNPs) overlapping the LD block tested, 35 involved trait pairs where one trait in the pair had genome-wide significant SNPs overlapping the LD block tested and 20 involved trait pairs where neither trait had genome-wide significant SNPs overlapping the LD block tested (Figure 2a). Thus, despite the targeted nature of our approach (which biased analyses towards LD blocks that contain genome-wide significant GWAS SNPs), 71% of the detected local r_g s linked genomic regions implicated by one of the six disease traits with seemingly unrelated disease traits. For example, LD block 1719 and 2281 both contained genome-wide significant GWAS SNPs from MDD and SCZ, an overlap which was mirrored by a significant local r_g between MDD and SCZ (Figure

- 139 **2b**). In addition, both LD blocks implicated disease traits that did not have overlapping genome-wide
- 140 significant GWAS SNPs in the region, indicating novel trait associations. These included (i) LBD in LD

141	block 1719, which negatively correlated with SCZ (ρ = -0.65, p = 4.72 x 10 ⁻⁶) and (ii) AD and PD, which
142	were positively correlated in LD block 2281 ($ ho$ = 0.41, p = 1.24 x 10 ⁻⁸). Notably, both LD blocks
143	contain genes of interest to traits implicated by local r_g analyses, including DRD2 in LD block 1719
144	(encodes dopamine receptor D2, a target of drugs used in both PD ⁷ and SCZ treatment ²⁷) and
145	<i>RAB27B</i> in LD block 2281 (encodes Rab27b, a Rab GTPase recently implicated in α -synuclein
146	clearance ²⁸)
147	Local r_g analyses also highlighted relationships between neurodegenerative traits in regions
148	containing well-known, disease-implicated genes, such as: (i) SNCA (implicated in monogenic and
149	sporadic forms of ${ m PD}^{3,5}$) in LD block 681, where a negative local r_g was observed between AD and PD
150	(ρ = -0.41, p = 6.51 x 10 ⁻¹³); (ii) CLU (associated with sporadic AD ^{19,29}) in LD block 1273 , where a
151	positive local r_g was observed between AD and PD (ρ = 0.36, p = 8.76 x 10 ⁻¹²); and finally, (iii) <i>APOE</i>
152	(E4 alleles associated with increased AD risk ³⁰) in LD block 2351, where r_g s were observed between
153	LBD and both AD and PD (LBD-AD: ρ = 0.59, p = 1.24 x 10 ⁻¹³⁹ ; LBD-PD: ρ = -0.29, p = 2.75 x 10 ⁻⁷)
154	(Figure 2c). We also noted a positive correlation between AD and PD in LD block 2128, which
155	contains the AD-associated KAT8 locus ¹⁹ and the PD-associated SETD1A locus ³ . Importantly, while a
156	genetic overlap between AD and PD has been previously reported at the MAPT locus (rs393152
157	shown to increase risk of both AD and PD^{31}), we were unable to replicate this association due to
158	insufficient univariate signal for AD in the LD block containing MAPT (LD block 2207, chr17:
159	43,460,501-44,865,832). In addition, we were unable to replicate a genetic overlap reported
160	between AD and PD in the HLA region (specifically in chr6: 31,571,218-32,682,664) ³² , as several of
161	the overlapping LD blocks (LD block 961-6, ranging across chr6: 31,427,210-32,682,213) had too few
162	overlapping SNPs between the 6 disease traits.

164 Sensitivity analysis indicates that by-proxy cases do not drive spurious local

165 correlations among neurodegenerative diseases

- 166 Given concerns that UK Biobank (UKBB) by-proxy cases could potentially be mislabelled (i.e. parents
- 167 of by-proxy case suffered from another type of dementia) and lead to spurious r_a s between
- 168 neurodegenerative traits, we performed sensitivity analyses using GWASs for AD and PD that
- 169 excluded UKBB by-proxy cases²⁰. Of the 21 LD blocks where significant local r_a s were observed
- 170 between the 3 neurodegenerative traits using AD and PD GWASs with by-proxy cases, only 2 (LD
- block 1273 and 2351) had sufficient local genetic signal for both AD and PD without by-proxy cases.
- 172 This likely reflects the decrease in cohort numbers when UKBB by-proxy cases are excluded from AD
- and PD GWASs (**Table 1**). We were able to replicate 2 of the 3 significant local r_a s observed in LD
- block 1273 and 2351, including the positive r_a between AD and PD in LD block 1273 and the positive
- 175 r_a between AD and LBD in LD block 2351 (Supplementary Figure 2, Supplementary Table 4). Further,
- while the local r_a between LBD and PD in LD block 2351 was non-significant when using the PD
- 177 GWAS without by-proxy cases, the correlation was in the same direction in the complementary
- analysis using the PD GWAS with by-proxy cases (no by-proxy: $\rho = -0.201$, ρ Cl = -0.443 to 0.007, p =

179 0.061; by-proxy: $\rho = -0.293$, $\rho Cl = -0.405$ to -0.184, $p = 2.75 \times 10^{-7}$) (Supplementary Figure 2,

180 Supplementary Table 4).

181

182 Local heritability of Lewy body dementia in an APOE-containing LD block is

183 only partly explained by Alzheimer's disease and Parkinson's disease

184 Eleven LD blocks were associated with > 1 trait pair, of which 8 LD blocks had a trait in common

across multiple trait pairs. In other words, the genetic component of one disease trait (the outcome

- trait) could be modelled using the genetic components of multiple predictor disease traits. This
- 187 included 3 LD blocks (758, 951 and 952) where all 3 neuropsychiatric disorders were significantly
- 188 correlated with one another, and thus could arguably be the outcome trait. In these situations, each

189	neuropsychiatric disorder was separately modelled as the outcome trait, resulting in 3 independent
190	models within each of these 3 LD blocks. The remaining 5 LD blocks only had 1 trait in common
191	across correlated trait pairs, therefore only one model was constructed for each. A total of 14
192	multivariate models were run across all 8 LD blocks, of which 6 models were found to contain a
193	predictor trait that significantly contributed to the local heritability of an outcome trait (Figure 3a,
194	Supplementary Table 5).
195	We noted that all models with a neuropsychiatric outcome trait and a significant neuropsychiatric
196	predictor trait had a high multivariate r^2 (range: 0.53-1), with upper confidence intervals including 1
197	(Figure 3b), suggesting that the genetic signal of the neuropsychiatric outcome trait could be entirely
198	explained by its predictor traits in these LD blocks. In contrast, in the APOE-containing LD block 2351,
199	which was modelled with LBD as the outcome and AD and PD as predictors, the multivariate r^2 was
200	0.43 (95% CI: 0.38 to 0.5), a result that held using GWASs for AD and PD that excluded by-proxy
201	cases (r^2 = 0.49, 95% CI: 0.44 to 0.57; Supplementary Figure 2). Thus, while AD and PD jointly
202	explained approximately 40% of the local heritability of LBD, a proportion of the local heritability for
203	LBD was independent of AD and PD.

204

205 Incorporation of gene expression traits to facilitate functional interpretation of

206 disease trait correlations

207 To dissect whether regulation of gene expression might underlie local r_q s between disease traits, we

208 performed local r_g analyses using expression quantitative trait loci (eQTLs) from eQTLGen³³ and

209 PsychENCODE³⁴, which represent large human blood and brain expression datasets, respectively

210 (Table 1). We restricted analyses to the 5 LD blocks highlighted in Figure 2 (LD blocks: 681, 1273,

211 1719, 2281, 2351), which contained genes of interest to at least one of the disease traits implicated

by local r_g analyses. From these LD blocks of interest, we defined genic regions (gene start and end

213 coordinates \pm 100 kb) for all overlapping protein-coding, antisense or lincRNA genes (n = 92).

214 We detected a total of 135 significant bivariate local r_q s across 47 distinct genic regions (FDR < 0.05), 215 with 43 local r_a s across 27 distinct genic regions between trait pairs involving a disease trait and a 216 gene expression trait (Supplementary Figure 3, Supplementary Table 6). We noted that the 217 explained variance (r^2) between trait pairs involving a disease trait and a gene expression trait 218 tended to be lower than between trait pairs involving two disease traits (Supplementary Figure 4), 219 an observation that aligns with a recent study that found only 11% of trait heritability to be 220 mediated by bulk-tissue gene expression³⁵. 221 With the exception of the SNCA-containing LD block 681, where eQTLs for only 1 out of 5 genes 222 tested in the block were correlated with a disease trait (negative r_a between blood-derived SNCA 223 eQTLs and PD), the expression of multiple genes was associated with disease traits across the 224 remaining LD blocks (Figure 4a). In addition, the expression of several genes was associated with 225 more than one disease trait (Figure 4b). For example, blood- and brain-derived ANKK1 eQTLs (DRD2-226 containing LD block 1719) were negatively correlated with both MDD and SCZ, which themselves 227 were positively correlated (Figure 4c). A SNP residing in the coding region of ANKK1 (rs1800497, 228 commonly known as TagIA SNP) has been previously associated with alcoholism, schizophrenia and 229 eating disorders, although it is unclear whether this SNP exerts its effect via DRD2 or ANKK1³⁶. As 230 DRD2 is not expressed in blood, and brain-derived DRD2 eQTLs did not pass the univariate test for 231 sufficient local genetic signal, we were unable to test for local r_a s between DRD2 eQTLs and any 232 neuropsychiatric disorder. The data available would therefore suggest that the shared risk of MDD 233 and SCZ in the overlapping ANKK1 and DRD2 genic regions may be partly driven by ANKK1 gene 234 expression. 235 A high degree of eQTL sharing across disease traits was observed in the *CLU*-containing LD block 236 1273, with blood-derived eQTLs from 5 out of the 6 genes implicated in local r_a s found to correlate 237 with both AD and PD (Figure 4b,d). This included situations where eQTL-disease trait correlations 238

had (i) the same direction of effect across both disease traits (as observed with PBK, PNOC and

239	SCARA5) or (ii) opposing directions of effect across both disease traits (as observed with CLU and
240	ESCO2) (Figure 4d). Notably, while a significant positive local r_g was observed between AD and PD in
241	the SCARA5 genic region (reflecting the positive local r_g observed between AD and PD across the
242	entire LD block), no local $r_{\!g}$ was observed between AD and PD in the CLU genic region, suggesting
243	that the shared risk of AD and PD in LD block 1273 may be driven by the expression of genes other
244	than the AD-associated CLU (Figure 4e). As a ferritin receptor involved in ferritin internalisation,
245	SCARA5 could plausibly drive shared AD and PD risk, given that cellular iron overload and iron-
246	induced oxidative stress have been implicated in several neurodegenerative diseases such as AD and
247	PD ^{37,38} .
248	Compared to LD block 1273, the degree of eQTL sharing across disease traits was lower in the APOE-
249	containing LD block 2351, with eQTLs from 4 out of 16 genes implicated in local r_g s found to
250	correlate with AD and one of PD or LBD (Figure 4b, f). Shared eQTL genes were only observed in
251	blood and included BCL3, CLPTM1, PVRL2 and TOMM40, with expression of BCL3 and CLPTM1
252	positively correlating with AD and PD and expression of <i>PVRL2</i> and <i>TOMM40</i> positively correlating
253	with AD and LBD. As the exception, <i>PVR</i> eQTLs were negatively associated with both AD and PD
254	albeit in different tissues: AD in brain and PD in blood. Expression of the remaining 11 genes was
255	exclusively associated with either AD (n = 8) or PD (n = 3). No significant local r_g was observed
256	between APOE eQTLs and AD (FDR < 0.05), although a nominal positive r_g was observed in blood ($ ho$ =
257	0.178, ρ CI = 0.007 to 0.352, p = 0.039; Supplementary Figure 3e, Supplementary Table 6). Overall,
258	these results indicate that risk of neurodegenerative diseases (in particular, AD) is associated with
259	expression of multiple genes in the APOE-containing LD block. Further, they add to a growing body
260	of evidence suggesting that in parallel with the well-studied APOE- $\varepsilon 4$ risk allele, there are additional
261	APOE-independent risk factors in the region (such as BCL3 ³⁹ and PVRL2 ⁴⁰) that may contribute to AD
262	risk.

- 263 For a complete overview of all genic regions tested across the 5 LD blocks of interest, see
- 264 Supplementary Figure 3 and Supplementary Table 6.

266 **Discussion**

267	Despite clinical and neuropathological overlaps between neurodegenerative diseases, global
268	analyses of genetic correlation (r_g) show minimal r_g among neurodegenerative diseases or across
269	neurodegenerative and neuropsychiatric diseases. However, local r_g s can deviate from the genome-
270	wide average estimated by global analyses and may even exist in the absence of a genome-wide r_g ,
271	thus motivating the use of tools to model local genetic relations.
272	Here, we applied LAVA to 3 neurodegenerative diseases and 3 neuropsychiatric disorders to
273	determine whether local r_g s exist in a subset of 300 LD blocks that contain genome-wide significant
274	GWAS loci from at least one of six investigated disease traits. We identified 77 significant bivariate
275	local r_g s across 59 distinct LD blocks, with 25 local r_g s between trait pairs where no significant global
276	$r_{\!g}$ was observed, including between (i) all 3 neurodegenerative diseases and SCZ and (ii) AD and PD.
277	Local r_g s highlighted expected associations (e.g. AD and LBD in the APOE-containing LD block 2351 ⁵)
278	and putative new associations (e.g. AD and PD in the CLU-containing LD block 1273) in genomic
279	regions containing well-known, disease-implicated genes. Likewise, incorporation of eQTLs
280	confirmed known relationships between diseases and genes, such as the association of AD with CLU
281	expression ²⁹ and PD with SNCA expression in blood ⁴¹ , and revealed putative new disease-gene
282	relationships. Together, these results indicate that more complex aetiological relationships exist
283	between neurodegenerative and neuropsychiatric diseases than those revealed by global r_g s.
284	Further, they highlight potential gene expression intermediaries that may account for local r_g s
285	between disease traits.
286	These findings have important implications for our understanding of neurodegenerative diseases
287	and the extent to which they overlap. An overlap between the synucleinopathies and AD is often
288	acknowledged in the context of LBD, which has been hypothesised to lie on a disease continuum
289	between AD and PD ^{5,42} . In support of this continuum, LBD was found to associate with both AD and
290	PD in the APOE-containing LD block 2351. Multiple regression analyses confirmed that AD and PD

291	were significant predictors of LBD heritability in LD block 2351. Importantly, when AD and PD were
292	modelled together, they explained only ~ 40% of the local heritability of LBD in LD block 2351,
293	implying that LBD represents more than the union of AD and PD. Further, the associations of AD and
294	PD with LBD had opposing regression coefficients, suggesting that the contribution of AD and PD to
295	LBD in the APOE locus may not be synergistic. This mirrors the observation that genome-wide
296	genetic risk scores of AD and PD do not interact in LBD, 5 and may indicate that different biological
297	pathways underlie the association between LBD and AD/PD. Indeed, only blood-derived PVRL2 and
298	TOMM40 eQTLs were found to correlate with both AD and LBD, while no shared eQTL genes were
299	detected between PD and LBD.
300	Less acknowledged is the genetic overlap between AD and PD, with no global $r_{\!g}$ reported between
301	the two diseases ^{16,43} and no significant evidence for the presence of loci that increase the risk of
302	both diseases ⁴⁴ . As the exception, genetic overlaps have been reported between AD and PD in the
303	HLA ³² and MAPT loci ³¹ , hinting that pleiotropy may exist locally. In support of local pleiotropy, we
304	observed 20 local r_g s between AD and PD in genomic regions containing disease-implicated genes,
305	such as SNCA (LD block 681) and CLU (LD block 1273). In the case of the CLU-containing LD block
306	1273, incorporation of eQTLs indicated that the association of AD and PD may be driven by the
307	expression of several genes, including the ferritin receptor SCARA5. In contrast, only blood-derived
308	SNCA eQTLs were associated with PD in LD block 681, suggesting that the association between AD
309	and PD at the SNCA locus could be driven by tissue- or context-dependent gene expression or
310	alternatively other molecular phenotypes.
311	A few studies have demonstrated genetic overlaps between neurodegenerative and
312	neuropsychiatric diseases, such as AD and BIP ⁴⁵ as well as AD and MDD ⁴⁶ , while others have
313	demonstrated no overlap ^{16,47} , with divergences in outcomes ascribed to differences in methodology
314	and cohort 46 . Here, we observed a local r_g between BIP and PD, in addition to local r_g s between
315	schizophrenia and all 3 neurodegenerative diseases, which in the case of LBD was observed in an LD

316 block containing the DRD2. Notably, parkinsonism in dementia with Lewy bodies (DLB, one of the two LBDs), is often less responsive to dopaminergic treatments than in PD⁴⁸. Furthermore, 317 318 methylation of the DRD2 promoter in leukocytes has been shown to differ between DLB and PD⁴⁹, 319 while D2 receptor density has been shown to be significantly reduced in the temporal cortex of DLB patients, but not AD⁵⁰, suggesting that the DRD2 locus may harbour markers that could distinguish 320 321 between these neurodegenerative diseases. Our study adds to the body of evidence in favour of a 322 shared genetic basis between neurodegenerative and neuropsychiatric diseases, although further 323 work will be required to determine whether this genetic overlap underlies the clinical and 324 epidemiological links observed between these two disease groups. 325 This study is not without its limitations, with several limitations related to the input data. These 326 limitations include: (i) the variability in cohort size, which in the case of the smallest GWAS, LBD, may 327 explain the limited number of local r_a s observed involving this trait; (ii) the risk of misdiagnosis; and 328 (iii) the lack of genetic diversity (i.e. all traits used were derived from individuals of European 329 ancestry). Given that population-specific genetic risk factors exist, such as the lack of MAPT GWAS signal in the largest GWAS of Asian patients with PD⁵¹, and that transethnic global r_a s between traits 330 such as gene expression are significantly less than 1^{52} , it is imperative that studies of local r_g are 331 332 expanded to include diverse populations. 333 Among methodological limitations, both LDSC and LAVA only consider autosomal chromosomes, leaving out chromosome X, which is not only longer than chromosome 8-22, but also encodes 858 334 and 689 protein-coding and non-coding genes, respectively (Ensembl v106)⁵³. Furthermore, as 335 336 mentioned by the developers of LAVA¹⁸, local r_a s could potentially be confounded by association 337 signals from adjacent genomic regions, a limitation which is particularly pertinent in our analysis of 338 gene expression traits where LD blocks were divided into smaller (often overlapping) genic regions. 339 Importantly, as with any genetic correlation analysis, an observed r_g does not guarantee the presence of true pleiotropy. Spurious r_g s can occur due to LD or misclassification¹⁷. Here, we 340

341	attempted to address the potential misclassification of by-proxy cases via sensitivity analyses using
342	GWASs for AD and PD that excluded UKBB by-proxy cases. We replicated 2 of the 3 significant local
343	r_g s observed in 2 LD blocks when using GWASs with by-proxy cases. However, we were unable to
344	test for local r_g s across the remaining 19 LD blocks due to insufficient univariate signal, which could
345	reflect (i) a genuine contribution of by-proxy cases to trait h^2 in the region or (ii) a lack of statistical
346	power to detect a genetic signal. Given the substantial decrease in cohort numbers when UKBB by-
347	proxy cases are excluded from AD and PD GWASs (Table 1), a lack of statistical power seems the
348	more likely explanation, warranting a revisit of this analysis as clinically-diagnosed and/or
349	pathologically-defined cohorts increase in size.
350	Finally, even where observed $r_{\!g}s$ potentially represent true pleiotropy, LAVA cannot discriminate
351	between vertical and horizontal pleiotropy (also known as mediated and biological pleiotropy,
352	respectively ^{17,18}). Thus, while incorporation of gene expression can provide testable hypotheses
353	regarding the underlying genes and biological pathways that drive relationships between
354	neurodegenerative and neuropsychiatric diseases, experimental validation is required to establish
355	the extent to which these genes represent genuine intermediary phenotypes.
356	In summary, our results have important implications for our understanding of the genetic
357	architecture of neurodegenerative and neuropsychiatric diseases, including the demonstration of
358	local pleiotropy particularly between neurodegenerative diseases. Not only do these findings suggest
359	that neurodegenerative diseases may share common pathogenic processes, highlighting putative
360	gene expression intermediaries which may underlie relationships between diseases, but they also
361	infer the existence of common therapeutic targets across neurodegenerative diseases that could be
362	leveraged for the benefit of broader patient groups.

363 Materials and methods

364 Trait pre-processing

365	GWAS summary statistics from a total of 8 distinct traits were used, including 6 disease traits and 2
366	gene expression traits. Gene expression traits were used to facilitate functional interpretation of
367	local genetic correlations (r_g) between disease traits. Disease traits included 3 neurodegenerative
368	diseases (Alzheimer's disease, AD; Lewy body dementia, LBD; and Parkinson's disease, PD) and 3
369	neuropsychiatric disorders (bipolar disorder, BIP; major depressive disorder, MDD; and
370	schizophrenia, SCZ) ^{3,19–23,54} . Gene expression traits included expression quantitative trait loci (eQTLs)
371	from eQTLGen ³³ and PsychENCODE ³⁴ , which represent large human blood and brain expression
372	datasets, respectively. All traits used were derived from individuals of European ancestry. Details of
373	all summary statistics used can be found in Table 1 . Where necessary, SNP genomic coordinates
374	were mapped to Reference SNP cluster IDs (rsIDs) using the SNPlocs.Hsapiens.dbSNP144.GRCh37
375	package 55 . In the case of the PD GWAS without UK Biobank (UKBB) data (summary statistics were
376	kindly provided by the International Parkinson Disease Genomics Consortium), additional quality
377	control filtering was applied, including removal of SNPs (i) with MAF < 1%, (ii) displaying an I^2
378	heterogeneity value of ≥1280 and (iii) where the SNP was not present in at least 9 out of the 13
379	cohorts included in the meta-analysis.

380

381 Global genetic correlation analysis and estimation of sample overlaps

Across disease trait pairs, LD score regression (LDSC) was used to (i) determine the global r_g and (ii) estimate sample overlap^{56,57}. The latter was used as an input for LAVA, given that potential sample overlap between GWASs could impact estimated local r_g s¹⁸. Summary statistics for each trait were pre-processed using LDSC's munge sumstats.py

386 (<u>https://github.com/bulik/ldsc/blob/master/munge_sumstats.py</u>) together with HapMap Project

387 Phase 3 SNPs⁵⁸. For the LD reference panel, 1000 Genomes Project Phase 3 European population

388	SNPs were used ⁵⁹ . Both HapMap Project Phase 3 SNPs and European LD Scores from the 1000
389	Genomes Project are made available by the developers of LDSC ^{56,57} from the following repository:
390	https://alkesgroup.broadinstitute.org/LDSCORE/ (see Key resources for details). Any shared
391	variance due to sample overlap was modelled as a residual genetic covariance. As performed by
392	Werme et al. ¹⁸ , a symmetric matrix was constructed, with off-diagonal elements populated by the
393	intercepts for genetic covariance derived from cross-trait LDSC and diagonal elements populated by
394	comparisons of each phenotype with itself. This symmetric matrix was then converted to a
395	correlation matrix. Importantly, it is not possible to estimate sample overlap with eQTL summary
396	statistics, but given that the cohorts used in the GWASs were different from the cohorts included in
397	the eQTL datasets, we assumed sample overlap between GWASs and eQTL datasets to be negligible.
398	Thus, they were set to 0 in the correlation matrix. However, given the inclusion of GTEx samples in
399	both eQTL datasets and our inability to estimate this overlap, downstream LAVA analyses were
400	performed separately for each eQTL dataset.
401	

402 Defining genomic regions for local genetic correlation analysis

403 Between disease traits

404	Genome-wide significant loci (p < 5 x 10^{-8}) were derived from publicly available AD, BIP, LBD, MDD,
405	PD and SCZ GWASs. Genome-wide significant loci were overlapped with linkage disequilibrium (LD)
406	blocks generated by Werme <i>et al.</i> ¹⁸ using a genome-wide partitioning algorithm. Briefly, each
407	chromosome was recursively split into blocks using (i) a break point to minimise LD between the
408	resulting blocks and (ii) a minimum size requirement. The resulting LD blocks represent
409	approximately equal-sized, semi-independent blocks of SNPs, with a minimum size requirement of
410	2,500 SNPs (resulting in an average block size of around 1Mb). Only those LD blocks containing
411	genome-wide significant GWAS loci from at least one trait were carried forward in downstream
412	analyses, resulting in a total of 300 autosomal LD blocks. Of the 22 possible autosomes, 21 contained

- 413 LD blocks with overlapping loci, with the highest number of LD blocks located in chromosome 1 and
- 414 6 (Supplementary Figure 1).

415 Between disease and gene expression traits

- 416 A total of 5 LD blocks, as highlighted by bivariate local r_q analysis of disease traits, were used in this
- 417 analysis (LD block 681, 1273, 1719, 2281 and 2351). From these LD blocks of interest, we defined
- 418 genic regions for all protein-coding, antisense or lincRNA genes that overlapped an LD block of
- 419 interest. Most lead *cis*-eQTL SNPs (i.e. the SNP with the most significant p-value in a SNP-gene
- 420 association) lie outside the gene start and end coordinates and are located within 100 kb of the
- 421 gene. Indeed, in eQTLGen, 55% of lead-eQTL SNPs were outside the gene body and 92% were within
- 422 100 kb from the gene³³. Thus, we extended genic regions with a 100-kb window (100 kb upstream
- 423 and 100 kb downstream of gene coordinates). These genic regions (n = 92) were carried forward in
- 424 downstream analyses.
- 425

426 Estimating bivariate local genetic correlations

427 Between disease traits

- 428 The detection of valid and interpretable local r_g requires the presence of sufficient local genetic
- 429 signal. For this reason, a univariate test was performed as a filtering step for bivariate local
- 430 r_q analyses. Bivariate local r_q analyses were only performed for pairs of disease traits which both
- 431 exhibited a significant univariate local genetic signal (p < 0.05/300, where the denominator
- 432 represents the total number of tested LD blocks). This step resulted in a total of 1,603 bivariate tests
- 433 spanning 275 distinct LD blocks. Bivariate results were considered significant when p < 0.05/1603.

434 Between disease and gene expression traits

- 435 For each genic region, only those disease traits that were found to have significant local r_a in the
- 436 associated LD block were carried forward to univariate and bivariate analyses with eQTL summary
- 437 statistics. As previously described, a univariate test was performed as a filtering step for bivariate
- local r_{g^g} analyses. Thus, bivariate local r_g analyses were only performed (i) if the gene expression

439	trait (i.e. eQTL genes) exhibited a significant univariate local genetic signal and (ii) for pairs of traits
440	(disease and gene expression) which both exhibited a significant univariate local genetic signal. A
441	cut-off of $p < 0.05/92$ (the denominator represents the total number of tested genic regions) was
442	used to determine univariate significance. A 100-kb window resulted in a total of 354 bivariate tests
443	spanning 55 distinct genic regions. Bivariate results were corrected for multiple testing using two
444	strategies: (i) a more lenient FDR correction and (ii) a more stringent Bonferroni correction (p <
445	0.05/n_tests, where the denominator represents the total number of bivariate tests). We discuss
446	results passing FDR < 0.05, but we make the results of both correction strategies available
447	(Supplementary Table 6, Supplementary Table 7).
448	We evaluated the effect of window size on bivariate correlations by re-running all analyses using a
449	50-kb window. Following filtering for significant univariate local genetic signal (as described above),
450	a total of 267 bivariate tests were run spanning 50 distinct genic regions. We detected 110
451	significant bivariate local r_g s (FDR < 0.05), 83 of which were also significant when using a 100-kb
452	window (Supplementary Figure 5). We observed strong positive Pearson correlations in local r_g
453	coefficient and p-value estimates across the two window sizes, indicating that our results are robust
454	to the choice of window size (Supplementary Figure 5). Of note, p-value estimates between disease
455	and gene expression traits tended to be lower when using the 50-kb window, as compared to the
456	100-kb window, as evidenced by the fitted line falling below the equivalent of $y = x$. This observation
457	may be a reflection of stronger <i>cis</i> -eQTLs tending to have a smaller distance between SNP and
458	gene ³³ . In contrast, p-value estimates between two disease traits were comparable across the two
459	window sizes.

460

461 Local multiple regression

462 For LD blocks with significant bivariate local r_g between one disease trait and ≥ 2 disease traits,

463 multiple regression was used to determine the extent to which the genetic component of the

- 464 outcome trait could be explained by the genetic components of multiple predictor traits. These
- 465 analyses permitted exploration of the independent effects of predictor traits on the outcome trait. A
- 466 predictor trait was considered significant when p < 0.05.

467

468 **Sensitivity analysis using by-proxy cases**

- 469 As UK Biobank (UKBB) by-proxy cases could potentially be mislabelled (i.e. parent of by-proxy case
- 470 suffered from another type of dementia) and lead to spurious r_a s between neurodegenerative traits,
- 471 we performed replication analyses using GWASs for AD²⁰ and PD that excluded UKBB by-proxy cases.
- 472 LD blocks were filtered to include only those where significant bivariate local r_a s were observed
- 473 between LBD and either by-proxy AD or by-proxy PD GWASs, in addition to between by-proxy AD
- 474 and by-proxy PD GWASs. These criteria limited the number of LD blocks to 21. Bivariate local
- 475 correlations were only performed for pairs of traits which both exhibited a significant univariate local
- 476 genetic signal (p < 0.05/21, where the denominator represents the total number of tested loci),
- 477 which resulted in a total of 10 bivariate tests spanning 6 distinct loci. We additionally performed
- 478 multiple regression in LD block 2351 using LBD as the outcome and AD and PD (both excluding UKBB

479 by-proxy cases) as predictors. A predictor trait was considered significant when p < 0.05.

480

481 R packages

- 482 All analyses were performed in R (v 4.0.5)⁶⁰. As indicated in the accompanying GitHub repository
- 483 (https://github.com/RHReynolds/neurodegen-psych-local-corr), all relevant packages were sourced
- 484 from CRAN, Bioconductor (via BiocManager⁶¹) or directly from GitHub. Figures were produced using
- 485 *circlize, ggplot2* and *ggraph*^{62–64}. All open-source software used in this paper is listed in **Key**

486 resources.

487

488 **Code availability**

- 489 Code used to pre-process GWASs, run genetic correlation analyses and to generate figures for the
- 490 manuscript are available at: <u>https://github.com/RHReynolds/neurodegen-psych-local-corr</u>
- 491 (doi:<u>10.5281/zenodo.6587707</u>). All other open-source software used in this paper is listed in **Key**
- 492 resources.

493

494 Data availability

- 495 Analyses in this study relied on publicly available data, all of which are listed in Key resources. In the
- 496 case of the PD GWAS without UK Biobank (UKBB) data, summary statistics were kindly provided by
- 497 the International Parkinson Disease Genomics Consortium: <u>https://pdgenetics.org/</u>.

498

499 Key resources

Resource	Source/Reference	Identifier/URL
Deposited Data		
Ensembl GRCh37 Ensembl v87	Ensembl genome	http://ftp.ensembl.org/pub/
	browser ⁵³	grch37/current/gtf/homo_s
		apiens/
eQTLGen eQTLs	Vosã <i>et al.,</i> 2021 ³³	https://www.eqtlgen.org/ci
	10	<u>s-eqtls.html</u>
GWAS, Alzheimer's disease (clinically diagnosed	Jansen <i>et al.</i> , 2019 ¹⁹	https://ctg.cncr.nl/software
+ UK Biobank proxy cases and controls)		<u>/summary_statistics</u>
GWAS, Alzheimer's disease (clinically	Kunkle <i>et al.,</i> 2019 ²⁰	https://www.niagads.org/ig
diagnosed)		ap-rv-summary-stats-
	22	<u>kunkle-p-value-data</u>
GWAS, Bipolar disease	Mullins <i>et al.</i> , 2021 ²²	https://www.med.unc.edu/
	r	pgc/download-results/
GWAS, Lewy body dementia	Chia <i>et al</i> ., 2021 [°]	https://www.ebi.ac.uk/gwa
	2	<u>s/studies/GCST90001390</u>
GWAS, Parkinson's disease excluding 23andMe	Nalls <i>et al.,</i> 2019°	https://pdgenetics.org/reso
		urces
GWAS, Major depressive disorder	Howard <i>et al.</i> , 2019 ²¹	https://www.med.unc.edu/
		pgc/download-results/
GWAS, Schizophrenia	Pardiñas <i>et al</i> ., 2018 ²³	https://www.med.unc.edu/
	. 10	pgc/download-results/
LAVA LD blocks	Werme <i>et al.,</i> 2021 ¹⁸	https://github.com/cadelee
		<u>uw/lava-partitioning</u>

LDSC: HapMap Project Phase 3 SNPs	International HapMap 3 Consortium ⁵⁸	https://alkesgroup.broadins titute.org/LDSCORE/; file	
LDSC: 1000 Genomes European LD Scores	1000 Genomes Project Consortium ⁵⁹	https://alkesgroup.broadins titute.org/LDSCORE/; file name:	
PsychENCODE eQTLs	Wang <i>et al.</i> , 2018 ³⁴	eur_w_ld_chr.tar.bz2 http://resource.psychencod e.org/	
Software			
Bioconductor		http://www.bioconductor.o	
BiocManager (v 1.30.16)	Morgan, 2021 ⁶¹	rg; RRID:SCR_006442 https://CRAN.R- project.org/package=BiocM	
CRAN		anager http://cran.r-project.org/; BRID:SCR_003005	
circlize (v 0.4.13)	Gu <i>et al.,</i> 2014 ⁶²	https://github.com/jokergo	
cowplot (v 1.1.1)	Wilke, 2020 ⁶⁵	https://CRAN.R-	
		ot: BRID:SCB_018081	
data.table (v 1.14.2)	Dowle and Srinivasan.	https://CRAN.R-	
	2021 ⁶⁶	project.org/package=data.ta	
doSNOW (y 10.19)	Microsoft and	DIE https://CRANR	
	Weston 2020 ⁶⁷	project org/package=doSNO	
	Weston, 2020	W	
foreach (v 1.5.1)	Microsoft and	https://CRAN.R-	
	Weston, 2020 ⁶⁸	project.org/package=foreac	
	,	h	
GenomicRanges (v 1.42.0)	Lawrence <i>et al.,</i> 2013 ⁶⁹	https://bioconductor.org/pa ckages/release/bioc/html/G	
		<u>enomicRanges.html;</u> RRID:SCR_000025	
ggbeeswarm (v 0.6.0)	Clarke and Sherrill-	https://CRAN.R-	
	Mix, 2017 ⁷⁰	project.org/package=ggbees warm	
ggplot2 (v 3.3.5)	Wickham, 2016 ⁶³	https://ggplot2.tidyverse.or	
a_{α}	Kassambara 2020^{71}	g; RRID:SCR_014601	
ggpubr (v 0.4.0)	Kassallibara, 2020	nicps.//CRAN.R-	
		; RRID:SCR_021139	
ggraph (v 2.0.5)	Pedersen, 2021 ⁶⁴	https://CRAN.R-	
		project.org/package=ggraph	
rtacle (v, 2, 0, 2)	$M_{\rm emperator} = 1.2021^{72}$; RRID:SCR_021239	
gtools (v 3.9.2)	warnes <i>et al.</i> , 2021	project.org/package=gtools	
here (v 1.0.1)	Müller, 2020 ⁷³	https://CRAN.R-	
ianitor (v 2 1 0)	Firke 2021 ⁷⁴	https://CRAN R-	
		project.org/package=janitor	

LAVA (v 0.0.6; commit #7be342)	Werme <i>et al.,</i> 2021 ¹⁸	https://github.com/josefin-
		werme/LAVA
LDSC (v 1.0.1)	Bulik-Sullivan <i>et al.</i> ,	https://github.com/bulik/ld
	2015'*	<u>SC</u>
openxlsx (v 4.2.4)	Schauberger and	https://CRAN.R-
	Walker, 2021 ⁷⁶	project.org/package=openxl
		<u>sx</u> ; RRID:SCR_019185
qdapTools (v 1.3.5)	Rinker, 2015 ⁷⁷	<u>http://github.com/trinker/q</u>
		<u>dapTools</u>
readxl (v 1.3.1)	Wickham and Bryan,	https://CRAN.R-
	2019 ⁷⁸	<pre>project.org/package=readxl;</pre>
		RRID:SCR_018083
R (v 4.0.5)	R Core Team ⁶⁰	http://www.r-project.org/;
		RRID:SCR_001905
rtracklayer (v 1.50.0)	Lawrence <i>et al.</i> , 2009 ⁷⁹	https://bioconductor.org/pa
		<pre>ckages/release/bioc/html/rt</pre>
		<u>racklayer.html;</u>
		RRID:SCR_021325
tidyverse (v 1.3.1)	Wickham et al., 2019 ⁸⁰	https://www.tidyverse.org/;
· · ·		RRID:SCR_019186

501 Acknowledgements

507	Funding
506	
505	enabling the completion of this study.
504	developing the above-mentioned analysis tools, for making them publicly available and thus
503	like to thank the scientific community behind all the GWAS datasets, as well as data scientists
502	We are grateful to Dr Cornelis Blauwendraat for feedback throughout this project. We would also

- 508 This research was funded in whole or in part by Aligning Science Across Parkinson's [Grant numbers:
- 509 ASAP-000478 and ASAP-000509] through the Michael J. Fox Foundation for Parkinson's Research
- 510 (MJFF). For the purpose of open access, the author has applied a CC BY public copyright license to all
- 511 Author Accepted Manuscripts arising from this submission.
- 512 AZW was supported through the award of a Clinical Research Fellowship funded by Eisai, Ltd and the
- 513 Wolfson Foundation. SWS was supported in part by the Intramural Research Program of the U.S.
- 514 National Institutes of Health (National Institute of Neurological Disorders and Stroke; project
- number: 1ZIANS003154). SAGT was supported by a Fonds de Recherche du Québec Santé Junior 1
- 516 Award and by operational funds from the Institut de valorisation des données (IVADO). MR was
- 517 supported through the award of a UKRI Medical Research Council Clinician Scientist Fellowship (MRC
- 518 Grant Code: MR/N008324/1). JH was supported through the UKRI Medical Research Council (MRC
- 519 Grant Code: MR/N026004/), the UK Dementia Research Institute, the Dolby Family Fund, and the
- 520 National Institute for Health Research University College London Hospitals Biomedical Research
- 521 Centre.
- 522

524 Author contributions

- 525 RHR, SAGT and MR conceived and designed the study. RHR and AZW analysed data and drafted the
- 526 figures. FLD, MS and SAGT consulted on the statistical analysis. SWS and MR provided clinical insight
- 527 to data interpretation. RHR wrote the initial manuscript. All authors contributed to the critical
- 528 analysis and revision of the manuscript.

529

530 Competing interests

- 531 AZW served as a medical monitor for Neuroscience Trials Australia, receiving no personal
- 532 compensation. SWS serves on the scientific advisory council of the Lewy Body Dementia Association
- and receives grant support from Cerevel Therapeutics.

534 **References**

- 535 1. Robinson, J.L., Lee, E.B., Xie, S.X., Rennert, L., Suh, E., Bredenberg, C., Caswell, C., Van Deerlin,
- 536 V.M., Yan, N., Yousef, A., et al. (2018). Neurodegenerative disease concomitant proteinopathies are
- 537 prevalent, age-related and APOE4-associated. Brain 141, 2181–2193.
- 538 2. De Jager, P.L., Yang, H.-S., and Bennett, D.A. (2018). Deconstructing and targeting the genomic
- architecture of human neurodegeneration. Nat. Neurosci. 21, 1310–1317.
- 540 3. Nalls, M.A., Blauwendraat, C., Vallerga, C.L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia,
- 541 D.A., Noyce, A.J., Xue, A., et al. (2019). Identification of novel risk loci, causal insights, and heritable
- risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet. Neurol. 18,
- 543 1091–1102.
- 4. Guerreiro, R., Ross, O.A., Kun-Rodrigues, C., Hernandez, D.G., Orme, T., Eicher, J.D., Shepherd,
- 545 C.E., Parkkinen, L., Darwent, L., Heckman, M.G., et al. (2018). Investigating the genetic architecture
- of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol. 17, 64–
- 547 74.
- 548 5. Chia, R., Sabir, M.S., Bandres-Ciga, S., Saez-Atienzar, S., Reynolds, R.H., Gustavsson, E., Walton,
- 549 R.L., Ahmed, S., Viollet, C., Ding, J., et al. (2021). Genome sequencing analysis identifies new loci
- associated with Lewy body dementia and provides insights into its genetic architecture. Nat. Genet.
- 551 53, 294–303.
- 552 6. Masters, C.L., Bateman, R., Blennow, K., Rowe, C.C., Sperling, R.A., and Cummings, J.L. (2015).
- 553 Alzheimer's disease. Nat. Rev. Dis. Prim. 1, 15056.
- 554 7. Poewe, W., Seppi, K., Tanner, C.M., Halliday, G.M., Volkmann, J., Schrag, A., Lang, A.E., Brundin, P.,
- 555 Volkmann, J., Schrag, A., et al. (2017). Parkinson disease. Nat. Rev. Dis. Prim. 3, 17013.
- 556 8. Kuring, J.K., Mathias, J.L., and Ward, L. (2018). Prevalence of Depression, Anxiety and PTSD in
- 557 People with Dementia: a Systematic Review and Meta-Analysis. Neuropsychol. Rev. 28, 393–416.

- 558 9. Reijnders, J.S.A.M., Ehrt, U., Weber, W.E.J., Aarsland, D., and Leentjens, A.F.G. (2008). A
- systematic review of prevalence studies of depression in Parkinson's disease. Mov. Disord. 23, 183–
 189; quiz 313.
- 561 10. Weintraub, D., Aarsland, D., Chaudhuri, K.R., Dobkin, R.D., Leentjens, A.F., Rodriguez-Violante,
- 562 M., and Schrag, A. (2022). The neuropsychiatry of Parkinson's disease: advances and challenges.
- 563 Lancet Neurol. 21, 89–102.
- 564 11. Ribe, A.R., Laursen, T.M., Charles, M., Katon, W., Fenger-Grøn, M., Davydow, D., Chwastiak, L.,
- 565 Cerimele, J.M., and Vestergaard, M. (2015). Long-term risk of dementia in persons with
- schizophrenia: A danish population-based cohort study. JAMA Psychiatry 72, 1095–1101.
- 567 12. Stroup, T.S., Olfson, M., Huang, C., Wall, M.M., Goldberg, T., Devanand, D.P., and Gerhard, T.
- 568 (2021). Age-Specific Prevalence and Incidence of Dementia Diagnoses among Older US Adults with
- 569 Schizophrenia. JAMA Psychiatry 78, 632–641.
- 570 13. Gustafsson, H., Nordström, A., and Nordström, P. (2015). Depression and subsequent risk of
- 571 Parkinson disease A nationwide cohort study. Neurology 84, 2422–2429.
- 572 14. Kazmi, H., Walker, Z., Booij, J., Khan, F., Shah, S., Sudre, C.H., Buckman, J.E.J., and Schrag, A.E.
- 573 (2021). Late onset depression: Dopaminergic deficit and clinical features of prodromal Parkinson's
- disease: A cross-sectional study. J. Neurol. Neurosurg. Psychiatry 92, 158–164.
- 575 15. Bellou, E., Stevenson-Hoare, J., and Escott-Price, V. (2020). Polygenic risk and pleiotropy in
- neurodegenerative diseases. Neurobiol. Dis. 142, 104953.
- 577 16. Brainstorm Consortium, Anttila, V., Bulik-Sullivan, B., Finucane, H.K., Walters, R.K., Bras, J.,
- 578 Duncan, L., Escott-Price, V., Falcone, G.J., Gormley, P., et al. (2018). Analysis of shared heritability in
- 579 common disorders of the brain. Science *360*, eaap8757.
- 580 17. van Rheenen, W., Peyrot, W.J., Schork, A.J., Lee, S.H., and Wray, N.R. (2019). Genetic correlations
- of polygenic disease traits: from theory to practice. Nat. Rev. Genet. 20, 567–581.

- 582 18. Werme, J., van der Sluis, S., Posthuma, D., and de Leeuw, C.A. (2022). An integrated framework
- 583 for local genetic correlation analysis. Nat. Genet. 54, 274–282.
- 584 19. Jansen, I.E., Savage, J.E., Watanabe, K., Bryois, J., Williams, D.M., Steinberg, S., Sealock, J.,
- 585 Karlsson, I.K., Hägg, S., Athanasiu, L., et al. (2019). Genome-wide meta-analysis identifies new loci
- and functional pathways influencing Alzheimer's disease risk. Nat. Genet. 51, 404–413.
- 587 20. Kunkle, B.W., Grenier-Boley, B., Sims, R., Bis, J.C., Damotte, V., Naj, A.C., Boland, A., Vronskaya,
- 588 M., van der Lee, S.J., Amlie-Wolf, A., et al. (2019). Genetic meta-analysis of diagnosed Alzheimer's
- 589 disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat. Genet. 51,
- 590 414-430.
- 591 21. Howard, D.M., Adams, M.J., Clarke, T.K., Hafferty, J.D., Gibson, J., Shirali, M., Coleman, J.R.I.,
- Hagenaars, S.P., Ward, J., Wigmore, E.M., et al. (2019). Genome-wide meta-analysis of depression
- identifies 102 independent variants and highlights the importance of the prefrontal brain regions.
- 594 Nat. Neurosci. 22, 343–352.
- 595 22. Mullins, N., Forstner, A.J., O'Connell, K.S., Coombes, B., Coleman, J.R.I., Qiao, Z., Als, T.D., Bigdeli,
- 596 T.B., Børte, S., Bryois, J., et al. (2021). Genome-wide association study of more than 40,000 bipolar
- disorder cases provides new insights into the underlying biology. Nat. Genet. 53, 817–829.
- 598 23. Pardiñas, A.F., Holmans, P., Pocklington, A.J., Escott-Price, V., Ripke, S., Carrera, N., Legge, S.E.,
- 599 Bishop, S., Cameron, D., Hamshere, M.L., et al. (2018). Common schizophrenia alleles are enriched in
- 600 mutation-intolerant genes and in regions under strong background selection. Nat. Genet. 50, 381-
- 601 389.
- 602 24. GBD 2019 Diseases and Injuries Collaborators (2020). Global burden of 369 diseases and injuries
- in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease
- 604 Study 2019. Lancet (London, England) *396*, 1204–1222.
- 605 25. Poewe, W., Seppi, K., Tanner, C.M., Halliday, G.M., Brundin, P., Volkmann, J., Schrag, A.-E., and

Lang, A.E. (2017). Parkinson disease. Nat. Rev. Dis. Prim. 3, 17013.

- 607 26. Erkkinen, M.G., Kim, M., and Geschwind, M.D. (2018). Clinical Neurology and Epidemiology of the
- 608 Major Neurodegenerative Diseases. Cold Spring Harb. Perspect. Biol. 10,.
- 609 27. Urs, N.M., Peterson, S.M., and Caron, M.G. (2017). New Concepts in Dopamine D2Receptor
- Biased Signaling and Implications for Schizophrenia Therapy. Biol. Psychiatry 81, 78–85.
- 611 28. Underwood, R., Wang, B., Carico, C., Whitaker, R.H., Placzek, W.J., and Yacoubian, T.A. (2020).
- 512 The GTPase Rab27b regulates the release, autophagic clearance, and toxicity of α-synuclein. J. Biol.
- 613 Chem. 295, 8005–8016.
- 614 29. Foster, E.M., Dangla-Valls, A., Lovestone, S., Ribe, E.M., and Buckley, N.J. (2019). Clusterin in
- 615 Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. Front. Neurosci.
- 616 *13*, 164.
- 617 30. Bertram, L., McQueen, M.B., Mullin, K., Blacker, D., and Tanzi, R.E. (2007). Systematic meta-
- 618 analyses of Alzheimer disease genetic association studies: The AlzGene database. Nat. Genet. 39,

619 17-23.

- 620 31. Desikan, R.S., Schork, A.J., Wang, Y., Witoelar, A., Sharma, M., McEvoy, L.K., Holland, D., Brewer,
- 521 J.B., Chen, C.H., Thompson, W.K., et al. (2015). Genetic overlap between Alzheimer's disease and
- 622 Parkinson's disease at the MAPT locus. Mol. Psychiatry 20, 1588–1595.
- 623 32. Stolp Andersen, M., Tan, M., Holtman, I.R., Hardy, J., and Pihlstrøm, L. (2022). Dissecting the
- 624 limited genetic overlap of Parkinson's and Alzheimer's disease. Ann. Clin. Transl. Neurol. 1–7.
- 625 33. Võsa, U., Claringbould, A., Westra, H.J., Bonder, M.J., Deelen, P., Zeng, B., Kirsten, H., Saha, A.,
- 626 Kreuzhuber, R., Yazar, S., et al. (2021). Large-scale cis- and trans-eQTL analyses identify thousands of
- 627 genetic loci and polygenic scores that regulate blood gene expression. Nat. Genet. 53, 1300–1310.
- 628 34. Wang, D., Liu, S., Warrell, J., Won, H., Shi, X., Navarro, F.C.P., Clarke, D., Gu, M., Emani, P., Yang,
- 629 Y.T., et al. (2018). Comprehensive functional genomic resource and integrative model for the human

- 631 35. Yao, D.W., O'Connor, L.J., Price, A.L., and Gusev, A. (2020). Quantifying genetic effects on disease
- 632 mediated by assayed gene expression levels. Nat. Genet. 52, 626–633.
- 633 36. Ponce, G., Pérez-González, R., Aragüés, M., Palomo, T., Rodríguez-Jiménez, R., Jiménez-Arriero,
- 634 M.A., and Hoenicka, J. (2009). The ANKK1 kinase gene and psychiatric disorders. Neurotox. Res. 16,
- 635 50-59.
- 636 37. Li, J.Y., Paragas, N., Ned, R.M., Qiu, A., Viltard, M., Leete, T., Drexler, I.R., Chen, X., Sanna-Cherchi,
- 637 S., Mohammed, F., et al. (2009). Scara5 Is a Ferritin Receptor Mediating Non-Transferrin Iron
- 638 Delivery. Dev. Cell 16, 35–46.
- 639 38. Crielaard, B.J., Lammers, T., and Rivella, S. (2017). Targeting iron metabolism in drug discovery
- and delivery. Nat. Rev. Drug Discov. 16, 400–423.
- 641 39. Nho, K., Kim, S., Horgusluoglu, E., Risacher, S.L., Shen, L., Kim, D., Lee, S., Foroud, T., Shaw, L.M.,
- 642 Trojanowski, J.Q., et al. (2017). Association analysis of rare variants near the APOE region with CSF
- and neuroimaging biomarkers of Alzheimer's disease. BMC Med. Genomics 10,.
- 644 40. Zhou, X., Chen, Y., Mok, K.Y., Kwok, T.C.Y., Mok, V.C.T., Guo, Q., Ip, F.C., Chen, Y., Mullapudi, N.,
- 645 Weiner, M.W., et al. (2019). Non-coding variability at the APOE locus contributes to the Alzheimer's
- 646 risk. Nat. Commun. 10, 1–16.
- 647 41. Locascio, J.J., Eberly, S., Liao, Z., Liu, G., Hoesing, A.N., Duong, K., Trisini-Lipsanopoulos, A.,
- Dhima, K., Hung, A.Y., Flaherty, A.W., et al. (2015). Association between α-synuclein blood
- transcripts and early, neuroimaging-supported Parkinson's disease. Brain 138, 2659–2671.
- 42. Jellinger, K.A. (2018). Dementia with Lewy bodies and Parkinson's disease-dementia: current
- 651 concepts and controversies. J. Neural Transm. 125, 615–650.
- 43. Guerreiro, R., Escott-Price, V., Darwent, L., Parkkinen, L., Ansorge, O., Hernandez, D.G., Nalls,
- 653 M.A., Clark, L., Honig, L., Marder, K., et al. (2016). Genome-wide analysis of genetic correlation in

⁶³⁰ brain. Science 362,.

- dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiol. Aging 38, 214.e7-
- 655 214.e10.
- 44. Moskvina, V., Harold, D., Russo, G.C., Vedernikov, A., Sharma, M., Saad, M., Holmans, P., Bras,
- 557 J.M., Bettella, F., Keller, M.F., et al. (2013). Analysis of genome-wide association studies of alzheimer
- disease and of parkinson disease to determine if these 2 diseases share a common genetic risk.
- 659 JAMA Neurol. 70, 1268–1276.
- 45. Drange, O.K., Bjerkehagen Smeland, O., Shadrin, A.A., Finseth, P.I., Witoelar, A., Frei, O., Wang,
- 661 Y., Hassani, S., Djurovic, S., Dale, A.M., et al. (2019). Genetic overlap between alzheimer's disease
- and bipolar disorder implicates the MARK2 and VAC14 genes. Front. Neurosci. 13, 1–11.
- 46. Lutz, M.W., Sprague, D., Barrera, J., and Chiba-Falek, O. (2020). Shared genetic etiology
- 664 underlying Alzheimer's disease and major depressive disorder. Transl. Psychiatry 10,.
- 47. Gibson, J., Russ, T.C., Adams, M.J., Clarke, T.K., Howard, D.M., Hall, L.S., Fernandez-Pujals, A.M.,
- 666 Wigmore, E.M., Hayward, C., Davies, G., et al. (2017). Assessing the presence of shared genetic
- architecture between Alzheimer's disease and major depressive disorder using genome-wide
- 668 association data. Transl. Psychiatry 7,.
- 48. McKeith, I.G., Boeve, B.F., Dickson, D.W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D.,
- 670 Galvin, J., Attems, J., Ballard, C.G., et al. (2017). Diagnosis and management of dementia with Lewy
- bodies: Fourth consensus report of the DLB Consortium. Neurology 89, 88–100.
- 49. Ozaki, Y., Yoshino, Y., Yamazaki, K., Ochi, S., Iga, J. ichi, Nagai, M., Nomoto, M., and Ueno, S. ichi
- 673 (2020). DRD2 methylation to differentiate dementia with Lewy bodies from Parkinson's disease. Acta
- 674 Neurol. Scand. *141*, 177–182.
- 50. Piggott, M.A., Ballard, C.G., Rowan, E., Holmes, C., McKeith, I.G., Jaros, E., Perry, R.H., and Perry,
- 676 E.K. (2007). Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy
- 677 bodies, association with cognitive decline. Synapse *61*, 903–911.

- 51. Foo, J.N., Chew, E.G.Y., Chung, S.J., Peng, R., Blauwendraat, C., Nalls, M.A., Mok, K.Y., Satake, W.,
- Toda, T., Chao, Y., et al. (2020). Identification of Risk Loci for Parkinson Disease in Asians and
- 680 Comparison of Risk Between Asians and Europeans: A Genome-Wide Association Study. JAMA
- 681 Neurol. 77, 746–754.
- 52. Brown, B.C., Asian Genetic Epidemiology Network Type 2 Diabetes Consortium, Ye, C.J., Price,
- 683 A.L., and Zaitlen, N. (2016). Transethnic Genetic-Correlation Estimates from Summary Statistics. Am.
- 684 J. Hum. Genet. *99,* 76–88.
- 53. Zerbino, D.R., Achuthan, P., Akanni, W., Amode, M.R., Barrell, D., Bhai, J., Billis, K., Cummins, C.,
- 686 Gall, A., Girón, C.G., et al. (2018). Ensembl 2018. Nucleic Acids Res. 46, D754–D761.
- 687 54. Chia, R., Sabir, M.S., Bandres-Ciga, S., Saez-Atienzar, S., Reynolds, R.H., Gustavsson, E., Walton,
- 688 R.L., Ahmed, S., Viollet, C., Ding, J., et al. (2020). Genome sequencing analysis identifies new loci
- associated with Lewy body dementia and provides insights into the complex genetic architecture.
- 690 BioRxiv 2020.07.06.185066.
- 691 55. Pagès, H. (2017). SNPlocs.Hsapiens.dbSNP144.GRCh37: SNP locations for Homo sapiens (dbSNP
- 692 Build 144). R Packag. Version 0.99.20.
- 56. Bulik-Sullivan, B., Loh, P.R., Finucane, H.K., Ripke, S., Yang, J., Patterson, N., Daly, M.J., Price, A.L.,
- Neale, B.M., Corvin, A., et al. (2015). LD score regression distinguishes confounding from polygenicity
- in genome-wide association studies. Nat. Genet. 47, 291–295.
- 696 57. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.-R., Duncan, L., Perry,
- 597 J.R.B., Patterson, N., Robinson, E.B., et al. (2015). An atlas of genetic correlations across human
- diseases and traits. Nat. Genet. 47, 1236–1241.
- 58. International HapMap 3 Consortium, Altshuler, D.M., Gibbs, R.A., Peltonen, L., Altshuler, D.M.,
- Gibbs, R.A., Peltonen, L., Dermitzakis, E., Schaffner, S.F., Yu, F., et al. (2010). Integrating common and
- rare genetic variation in diverse human populations. Nature *467*, 52–58.

- 702 59. 1000 Genomes Project Consortium, Auton, A., Brooks, L.D., Durbin, R.M., Garrison, E.P., Kang,
- H.M., Korbel, J.O., Marchini, J.L., McCarthy, S., McVean, G.A., et al. (2015). A global reference for
- human genetic variation. Nature *526*, 68–74.
- 60. R Core Team (2021). R: A language and environment for statistical computing.
- 706 61. Morgan, M. (2021). BiocManager: Access the Bioconductor Project Package Repository.
- 707 62. Gu, Z., Gu, L., Eils, R., Schlesner, M., and Brors, B. (2014). circlize Implements and enhances
- ros circular visualization in R. Bioinformatics *30*, 2811–2812.
- 63. Wickham, H. (2016). ggplot2: Elegant Graphics for Data Analysis (Springer-Verlag New York).
- 710 64. Pedersen, T.L. (2021). ggraph: An Implementation of Grammar of Graphics for Graphs and
- 711 Networks.
- 712 65. Wilke, C.O. (2020). cowplot: Streamlined Plot Theme and Plot Annotations for "ggplot2."
- 713 66. Dowle, M., and Srinivasan, A. (2021). data.table: Extension of `data.frame`.
- 714 67. Corporation, M., and Weston, S. (2020). doSNOW: Foreach Parallel Adaptor for the "snow"
- 715 Package.
- 716 68. Microsoft, and Weston, S. (2020). foreach: Provides Foreach Looping Construct.
- 717 69. Lawrence, M., Huber, W., Pagès, H., Aboyoun, P., Carlson, M., Gentleman, R., Morgan, M.T., and
- 718 Carey, V.J. (2013). Software for Computing and Annotating Genomic Ranges. PLoS Comput. Biol. 9,
- 719 e1003118.
- 720 70. Clarke, E., and Sherrill-Mix, S. (2017). ggbeeswarm: Categorical Scatter (Violin Point) Plots.
- 721 71. Kassambara, A. (2020). ggpubr: "ggplot2" Based Publication Ready Plots.
- 722 72. Warnes, G.R., Bolker, B., and Lumley, T. (2021). gtools: Various R Programming Tools.
- 723 73. Müller, K. (2020). here: A Simpler Way to Find Your Files.
- 724 74. Firke, S. (2021). janitor: Simple Tools for Examining and Cleaning Dirty Data.

- 725 75. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.-R.R., Duncan, L., Perry,
- J.R.B.B., Patterson, N., Robinson, E.B., et al. (2015). An atlas of genetic correlations across human
- diseases and traits. Nat. Genet. 47, 1236–1241.
- 728 76. Schauberger, P., and Walker, A. (2021). openxlsx: Read, Write and Edit xlsx Files.
- 729 77. Rinker, T.W. (2015). {qdapTools}: Tools to Accompany the qdap Package.
- 730 78. Wickham, H., and Bryan, J. (2019). readxl: Read Excel Files.
- 731 79. Law rence, M., Gentleman, R., and Carey, V. (2009). rtracklayer: An R package for interfacing with
- 732 genome browsers. Bioinformatics 25, 1841–1842.
- 733 80. Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes,
- A., Henry, L., Hester, J., et al. (2019). Welcome to the Tidyverse. J. Open Source Softw. 4, 1686.

736 **Figures**







738

Figure 1 Overview of local and global genetic correlations between neurodegenerative diseases and neuropsychiatric disorders.

(a) Chord diagram showing the number of significant bivariate local s (p < 0.05/1603) between each of the disease traits across all LD blocks. Positive and negative correlations are coloured red and blue, respectively.
(b) Comparison between the global s estimated by LDSC (bottom) and the mean local from LAVA (top) across all tested LD blocks. Significant global s (p < 0.05/15) are indicated with *. The number of significant local s is indicated by a number in each tile. (c) Bar plot showing the number of significant local s between disease trait pairs. The fill of the bars indicates the number of significant LD blocks for which the upper limit of

747 the 95% confidence interval (CI) included 1.



750 Figure 2 Local analyses associate disease-implicated genomic regions with previously unrelated traits.

751 (a) Bar plot (left) showing the number of traits within trait pairs demonstrating significant local s that had 752 genome-wide significant SNPs overlapping the tested LD block (as illustrated by the schematic on the right). (b) 753 Two LD blocks illustrating the situations depicted in (a). Edge diagrams for each LD block show the 754 standardised coefficient for (rho, ρ) for each significant bivariate local \cdot . Significant negative and positive 755 s are indicated by blue and red colour, respectively. (c) Heatmaps show the rho for each bivariate local 756 within the LD block. Asterisks (*) indicate s that were replicated when using AD and PD GWASs that excluded 757 UK Biobank by-proxy cases. Significant negative and positive s are indicated by blue and red fill, respectively. 758 Non-significant s have a grey fill. In both (b) and (c) panels are labelled by the LD block identifier, the traits 759 with genome-wide significant SNPs overlapping the LD block (indicated in the brackets) and the genomic 760 coordinates of the LD block (in the format chromosome:start-end).





762 Figure 3 Multiple regression across LD blocks with multiple trait pair correlations.

For both plots, only those multiple regression models with at least one significant predictor (p < 0.05) are
shown. (a) Plots of standardised coefficients for each predictor in multiple regression models across each LD
block, with whiskers spanning the 95% confidence interval for the coefficients. Panels are labelled by the LD
block identifier and the regression model. (b) Multivariate for each LD block and model, where multivariate
represents the proportion of variance in genetic signal for the outcome trait explained by all predictor traits
simultaneously. Whiskers span the 95% confidence interval for the . ***, p < 0.001; **, p < 0.05.



770 Figure 4 Incorporation of gene expression traits to facilitate functional interpretation of disease trait 771 correlations.

- (a) Bar plot of the number of eQTL genes (as defined by their genic regions) tested in each LD block. The fill of
- the bars indicates whether eQTL genes were significantly correlated with at least one disease trait. (b) Bar plot
- of the number of eQTL genes that were significantly correlated with at least one disease trait. The fill of the
- bars indicates whether eQTL genes in local r_g s were correlated with one or more disease traits. (c, d, f)
- Heatmaps of the standardised coefficient for r_a (rho) for each significant gene expression-disease trait
- correlation (FDR < 0.05) within LD block (c) 1719, (d) 1273 and (f) 2351. Genes are ordered left to right on the
- x-axis by the genomic coordinate of their gene start. Panels are labelled by the eQTL dataset from which eQTL
- genes were derived (either PsychENCODE's analysis of adult brain tissue from 1387 individuals or the eQTLGen
- 780 meta-analysis of 31,684 blood samples from 37 cohorts). (e) Edge diagrams for representative genic regions
- show the rho for each significant bivariate local r_g (FDR < 0.05). GWAS and eQTL nodes are indicated by grey
- and white fill, respectively. Panels are labelled by the gene tested and the eQTL dataset from which eQTL
- genes were derived. In panels c-f significant negative and positive r_g s are indicated by blue and red colour,
- 784 respectively.

<u>Tables</u>

Table 1 Overview of traits included in this study. Global SNP heritability (h²) for each trait was obtained using LDSC⁷⁵. SE, standard error.

Trait type	Trait	Abbreviation	N	N cases	N controls	Global h ² (SE)	Original study
Disease	Alzheimer's disease Clinically diagnosed + UK Biobank proxy cases and controls	AD	455,258	71,880 (46,613 proxy)	383,378 (318,246 proxy)	1.5% (0.2)	Jansen <i>et al.,</i> 2019 ¹⁹
Disease	Alzheimer's disease Clinically diagnosed	AD (no proxy)	63,926	21,982	41,944	7.1% (1.1)	Kunkle <i>et al.</i> , 2019 ²⁰
Disease	Bipolar disorder	BIP	413,466	41,917	371,549	7.1% (0.3)	Mullins <i>et al.,</i> 2021 ²²
Disease	Lewy body dementia Autopsy-confirmed + clinically diagnosed	LBD	6,618	2,591 (1,789 autopsy- confirmed)	4,027	17.1% (7.6)	Chia <i>et al.</i> , 2021⁵
Disease	Major depressive disorder	MDD	500,199	170,756	329,443	6% (0.2)	Howard <i>et al.,</i> 2019 ²¹
Disease	Parkinson's disease excluding 23andMe Clinically diagnosed + UK Biobank proxy cases and controls	PD	482,730	33,674 (18,618 proxy)	449,056 (436,419 proxy)	1.9% (0.2)	Nalls <i>et al.</i> , 2019 ³
Disease	Parkinson's disease excluding 23andMe Clinically diagnosed	PD (no proxy)	27,693	15,056	12,637	30.6% (2.8)	Nalls <i>et al.,</i> 2019 ³
Disease	Schizophrenia	SCZ	105,318	40,675	64,643	41% (1.4)	Pardiñas <i>et al.,</i> 2018 ²³
Gene expression	eQTLGen Blood-derived eQTLs	eQTLGEN	31,684	-	-	-	Vosã <i>et al.,</i> 2021 ³³
Gene expression	PsychENCODE Brain-derived eQTLs	PSYCHENCODE	1,387	-	-	-	Wang <i>et al.</i> , 2018 ³⁴

Supplementary Figures



Supplementary Figure 1 (a) Number of LD blocks containing genome-wide significant loci per chromosome. Chromosomes have been ordered by the total number of LD blocks in each chromosome. **(b)** Number of genome-wide significant AD, BIP, LBD, MDD, PD and SCZ SNPs per autosome.



Supplementary Figure 2 Impact of excluding UK Biobank by-proxy cases on local genetic correlations and multiple regression.

(a) Scatter plot of -log10(p-value) and the standardised coefficient for (rho, p) for each pair of phenotypes with sufficient univariate signal to carry out a bivariate test using AD/PD GWASs with or without by-proxy cases. In each panel, Pearson's coefficient (R) and associated p-value (p) are displayed. The black dashed line represents the line y = x. Points are coloured, where applicable, by whether they share the same direction of effect. (b) Significant bivariate local genetic correlations using AD/PD GWASs with or without by-proxy cases (as indicated in panel headers). Heatmaps show the rho for all tested associations within the LD block, with significant negative and positive correlations indicated by blue and red fill, respectively. Non-significant correlations have a grey fill. (c) Results of multiple regression model across LD block 2351. Plot (left) of standardised coefficients for each predictor in multiple regression model in LD block 2351, with whiskers spanning the 95% confidence interval for the coefficients. Plot (right) of multivariate for LD block 2351, where multivariate represents the proportion of variance in genetic signal for LBD explained by AD and PD simultaneously. Whiskers span the 95% confidence interval for the multivariate .***, p < 0.001.



Supplementary Figure 3 Local gene expression and disease trait correlations across 5 LD blocks of interest.

Heatmaps of the standardised coefficient for r_g (rho) for all tested gene expression-disease trait correlation within LD block (a) 681, (b) 1273, (c) 1719, (d) 2281 and (e) 2351. All negative and positive r_g s with p < 0.05 are indicated by blue and red colour, respectively, while the remainder have a grey fill. Significant local r_g s (FDR < 0.05) are indicated by two asterisks (**), while nominally significant local r_g s (p < 0.05) are indicated with a black square (\square). Genes are ordered left to right on the x-axis by the genomic coordinate of their gene start.



Supplementary Figure 4 Explained variance in trait pairs with different trait types.

Boxplot of explained variance (r^2 , the proportion of variance in genetic signal of one disease trait in a pair explained by the other) in trait pairs involving a disease and gene expression trait (gwas-eqtl) or two disease traits (gwas-gwas). Only local r_q s that passed significance are plotted (FDR < 0.05; N, local r_q s = 87).



Supplementary Figure 5 Effect of window size on local genetic correlations.

(a) Number of significant bivariate local 's across window sizes. Bars are coloured by whether 's are significant across both window sizes (shared) or only one (unique). (b) Scatter plot of $-\log 10(p-value)$ and the standardised coefficient for (rho, p) for each pair of phenotypes that could be tested across genic regions with a 50-kb or 100-kb window. Panels indicate whether the pair of phenotypes included a disease and gene expression trait (gwas-eqtl) or two disease traits (gwas-gwas). Points are coloured by whether they share the same direction of effect. The black line represents a linear model fitted to the data, with the 99% confidence interval indicated with a grey fill. Further, Pearson's coefficient (R) and associated p-value (p) are displayed. The red dashed line represents the line y = x.

Supplementary Tables

Supplementary Table 1 LD blocks, their associated disease traits (as determined by overlap of genome-wide significant SNPs) and overlapping genes.

Supplementary Table 2 Results of LDSC using the six disease traits.

Supplementary Table 3 Results of LAVA using the six disease traits.

Supplementary Table 4 Results of LAVA using GWASs for AD and PD that exclude UK Biobank by-proxy cases.

Supplementary Table 5 Results of multiple regression analyses.

Supplementary Table 6 Results of LAVA using disease and gene expression traits (100-kb window). Sheets containing bivariate results for each LD block also contain (a) locus plot of genic regions (including 100-kb window). Significant bivariate local genetic correlations between a disease and gene expression trait are highlighted in blue (FDR < 0.05). (b) Edge diagrams for genic regions where a significant bivariate local genetic correlation was observed between a disease and gene expression trait (FDR < 0.05). Edges diagrams for significant bivariate local genetic correlation was observed between a disease and gene expression trait (FDR < 0.05). Edges display the standardised coefficient for genetic correlation (rho) for significant bivariate local genetic correlations, with negative and positive correlations indicated by blue and red colour, respectively. GWAS and eQTL nodes are indicated by grey and white fill, respectively.

Supplementary Table 7 Results of LAVA using disease and gene expression traits (50-kb window). Sheets containing bivariate results for each LD block also contain (a) locus plot of genic regions (including 50-kb window). Significant bivariate local genetic correlations between a disease and gene expression trait are highlighted in blue (FDR < 0.05). (b) Edge diagrams for genic regions where a significant bivariate local genetic correlation was observed between a disease and gene expression trait (FDR < 0.05). Edges display the standardised coefficient for genetic correlation (rho) for significant bivariate local genetic correlations, with negative and positive correlations indicated by blue and red colour, respectively. GWAS and eQTL nodes are indicated by grey and white fill, respectively.